<?xml version="1.0" encoding="UTF-8"?>
<p>Schistosomiasis affects an estimated 219 million people globally. PZQ is the only medication currently employed in mass drug administration (MDA) programs. However, as PZQ is not effective against immature schistosomes, repeated administration may be needed to ensure complete parasite clearance (as juvenile worms progress to maturity) and achieve acceptable cure rates. Reliance on a single agent also markedly increases the risk that resistance will develop [
 <xref rid="B7-tropicalmed-04-00053" ref-type="bibr">7</xref>,
 <xref rid="B8-tropicalmed-04-00053" ref-type="bibr">8</xref>]. There is a critical need to develop new therapeutics that target essential pathways that are not altered by PZQ. 
</p>
